Document is current
Any future updates will be listed below
-
Authors
Yokoi, Katsunori
Hattori, Makoto
Satake, Yuki
Tanaka, Yasuhiro
Sato, Maki
Hashizume, Atsushi
Hori, Akihiro
Kawashima, Motoshi
Hirakawa, Akihiro
Watanabe, Hirohisa
Katsuno, Masahisa
-
Funding
Funding for this research was provided by:
The Research Funding for Longevity Sciences (28-8, 19-20)
Japan Agency for Medical Research and Development (19dk0207027h0004, 19lk0201101h0001, 19dm0107155h0001)
- License Information
-
More Information
Article History
Received: 27 March 2020
Accepted: 10 November 2020
First Online: 25 November 2020
Competing interests
: Drs. Yokoi, Hattori, Satake, Tanaka, Sato, Hashizume, Hori, Kawashima and Hirakawa report no disclosures. Dr. Watanabe is supported by Otsuka Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., FP Pharmaceutical Corporation, Eisai Co. Ltd., Daiichi Sankyo Company Limited and Novartis Pharma K.K., and grants from Otsuka Pharmaceutical Co. Ltd. and FUJIFILM RI Pharma Co. Ltd. Dr. Katsuno is supported by a JSPS KAKENHI Grant Number JP17H04195, grants from the Japan Agency for Medical Research and Development (Nos. 19ek0109221h0003, 19ek0109359h0002, 19dk0207027h0004, 19lk0201101h0001 and 19dm0107155h0001), a grant from the Naito Foundation and a grant from the Hori Sciences and Arts Foundation. He received honoraria from Takeda Pharmaceutical Co. Ltd., Alnylam Japan, Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Novartis Pharma Co. Ltd., Biogen Japan and UCB Japan and grants from Zenyaku Kogyo Co. Ltd., Japan Blood Products Organization, Mitsubishi-Tanabe Pharma, CSL Behring Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., Otsuka Pharmaceutical Co. Ltd. and Daiichi Sankyo Co. Ltd.
